HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Dickinson Named Acting Chief Counsel Following Tyler’s Departure

This article was originally published in The Rose Sheet

Executive Summary

FDA has tapped Elizabeth Dickinson for acting chief counsel, effective Aug. 7. Dickinson is taking the post on an interim basis while the agency seeks a permanent successor to Ralph Tyler.

You may also be interested in...



In Brief

Democratic Senators ask FDA to set maximum lead limits for lipstick. More news in brief.

FDA News In Brief

Dickinson installed as permanent chief counsel; Schwabe’s Umcka homeopathics deemed new drugs for cold/flu claims; inadequate GMPs weigh on Vitagenic; more FDA In Brief.

FDA News In Brief

Dickinson installed as permanent chief counsel; Schwabe’s Umcka homeopathics deemed new drugs for cold/flu claims; inadequate GMPs weigh on Vitagenic; more FDA In Brief.

Related Content

UsernamePublicRestriction

Register

RS017663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel